EyePoint to halve workforce after experimental drug fails second late-stage trial
EyePoint to halve workforce after experimental drug fails second late-stage trial
EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company developing sustained-release therapeutics for serious eye disorders, including age-related macular degeneration (AMD) and diabetic macular edema. Its lead program, DURAVYU, is an intravitreal implant delivering a tyrosine kinase inhibitor for sustained VEGF suppression.
Following a second pivotal Phase 3 primary-endpoint miss for DURAVYU (intravitreal vorolanib insert) in wet age-related macular degeneration (wet AMD), EyePoint terminated its late-stage wet AMD trials early, filed Massachusetts WARN notices to cut 105 positions (~53% of staff) across its Watertown and Northbridge facilities, and shifted clinical capital toward diabetic macular edema (DME).
EyePoint to halve workforce after experimental drug fails second late-stage trial
Latest Fierce Pharma coverage of EyePoint phase 3 for AMD disappoints, tanking stock
Reuters reports EyePoint's eye drug missed its main goal in a late-stage trial, sending shares tumbling.
BioSpace reports EyePoint Pharmaceuticals stock dropped sharply after its Phase 3 AMD drug failed, intensifying the next-generation macular degeneration competition.